Pfizer's Lyme Vaccine Works. So Why Did the Trial Technically Fail?

In statistical terms, fewer events mean wider confidence intervals. Wider confidence intervals mean more uncertainty, even when the actual effect size is strong. It's like trying to prove you're a great free-throw shooter, but the refs only let you take five shots instead of fifty. You might sink four of them, but nobody's ready to call you Steph Curry based on that sample.

A secondary pre-specified analysis (measuring efficacy from just one day after the fourth dose instead of 28 days) did clear the bar, showing 74.8% efficacy with a lower bound of 21.7%. Same vaccine. Same trial. Slightly different measurement window. Suddenly the stats cooperate.

The Ghost of LYMErix

This isn't the first time a Lyme vaccine has had a complicated story. Back in 1998, a vaccine called LYMErix won FDA approval with about 78% efficacy. It should have been a public health triumph.

Instead, it became a cautionary tale. Fears about autoimmune side effects spread (later studies found no unusual safety signal), lawsuits piled up, anti-vaccine sentiment grew, and sales cratered. By 2001, the manufacturer was pulling in just $5 million annually. SmithKline Beecham pulled it from the market in 2002, citing poor sales. As Lyme expert Allen Steere put it: the withdrawal was driven by "fear and lawsuits, not scientific findings."

For 24 years since, nobody has brought another Lyme vaccine to market. Pfizer and Valneva's candidate is the only advanced program in development. There is no Plan B.

The Regulatory Poker Game

Pfizer says it's pushing ahead with submissions to both the FDA and EMA in 2026. The company's pitch is straightforward: the vaccine showed clinically meaningful protection, the safety profile was clean (no concerns flagged in the trial), and the primary endpoint miss was a statistical artifact caused by low case counts, not by a weak vaccine.

Pfizer's Chief Vaccines Officer called the 70%-plus efficacy "highly encouraging" for preventing a disease with serious long-term consequences. Valneva, the smaller French biotech that originally developed the vaccine, is treating the results as a major milestone.

But regulators don't hand out approvals for moral victories. The FDA cares about pre-specified endpoints for a reason: they prevent companies from cherry-picking whatever analysis looks best after the fact. The secondary analysis helps Pfizer's case, but it wasn't the primary one. That distinction will matter in review meetings.

Dr. Martin Becker of NYU Grossman Long Island School of Medicine struck an optimistic tone, noting that prior trials had already confirmed safety and immune response, and that "higher case numbers would boost confidence." Tick-borne disease specialists have generally called the results promising, while flagging that the real-world impact needs more scrutiny.

The Stakes Are Bigger Than One Trial

Lyme disease isn't standing still. Reported U.S. cases have more than quintupled since 2001, climbing from under 17,000 to over 89,000 in 2023. In Europe, an estimated 129,000 to 132,000 cases occur annually, with incidence rising as climate change pushes ticks into new territory. Germany's Saxony region saw cases jump 61% in 2025 compared to the prior year.

The CDC's expanded estimates suggest surveillance only captures about 20% of actual diagnoses. Pennsylvania alone reported an incidence of 128 per 100,000 people in 2023. Geographic spread is accelerating southeastward from the traditional hotspots in the Northeast and upper Midwest.

All of which means the unmet need is enormous and growing. A vaccine that cuts Lyme cases by 73% could prevent hundreds of thousands of infections every year. The question is whether a statistical technicality will delay or derail that outcome.

What Happens Next

Pfizer has invested heavily in this program. The partnership with Valneva kicked off in 2020 with a $130 million upfront payment, and Valneva is eligible for up to $308 million in total upfront and milestone payments combined. Pfizer also took a $95 million equity stake in Valneva in 2022. Walking away from all of that isn't really on the table.

The most likely path forward: Pfizer files with regulators, leans heavily on the secondary analysis and the strong point estimate, and argues that the primary miss was a fluke of lower-than-expected disease incidence. The FDA might agree and approve. It might request additional data. Or it might say the bar is the bar.

For the millions of people in tick country who check themselves for tiny black dots every summer, the answer can't come soon enough. The vaccine works. Whether the paperwork agrees is another question entirely.